✦ LIBER ✦

Phase II study of transdermal estradiol in androgen-independent prostate carcinoma

✍ Scribed by Lisa B. Bland; Mark Garzotto; Thomas G. DeLoughery; Christopher W. Ryan; Kathryn G. Schuff; Emily M. Wersinger; Dianne Lemmon; Tomasz M. Beer

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 84 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20857

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of transdermal estradiol

Phase II study of transdermal estradiol in androgen-independent prostate carcinoma

✍ Manish Kohli 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 1 views

Multicenter Phase II study of estramusti

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma

✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho

Selective aromatase inhibition for patie

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma : A Phase II study of letrozole

✍ Matthew R. Smith; Donald Kaufman; Daniel George; William K. Oh; Maryanne Kazanis 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

## Background: First and second-generation aromatase inhibitors have shown activity in patients with androgen-independent prostate carcinoma. these early-generation aromatase inhibitors are nonselective, however, and inhibition of other steroidogenic enzymes may contribute to their reported clinica

Vinorelbine and estramustine in androgen

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer : A Phase II study

✍ Matthew R. Smith; Donald Kaufman; William Oh; Kimberly Guerin; Michael Seiden; T 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

Phase II trial of oral cyclophosphamide,

Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma

✍ Beth Hellerstedt; Kenneth J. Pienta; Bruce G. Redman; Peg Esper; Rodney Dunn; Ju 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

## Abstract ## BACKGROUND The authors evaluated the combination of oral cyclophosphamide, oral prednisone, and diethylstilbestrol (DES) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Thirty‐seven patients with prostate carcinoma refractory to androgen ablation who ha

Phase II trial of cyclophosphamide, vinc

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma

✍ Danai D. Daliani; Vasily Assikis; Shi-Ming Tu; Christos N. Papandreou; Lance C. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Abstract ## BACKGROUND In this Phase II study, the authors assessed the toxicity and anti‐tumor activity of a combination of oral cyclophosphamide, oral low‐dose dexamethasone, and intravenous vincristine (CVD) in patients with metastatic androgen‐independent prostate carcinoma (AI‐PCa). ## ME